Rise Advisors’s Gyre Therapeutics GYRE Stock Holding History

Rise Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-54	Closed	-$397	–	1558
2025 Q2	$397	Buy	+54	New	+$471	﹤0.01%	1453

Other funds holding GYRE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Rise Advisors's GYRE Position: Q3 2025 in Review

Rise Advisors sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 54 shares — an estimated $397 sold.

Rise Advisors first reported a position in GYRE in Q2 2025 and held it in 1 quarter. The position peaked at $397 in Q2 2025. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.

Rise Advisors reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
Rise Advisors sold 54 Gyre Therapeutics shares in Q3 2025, an estimated $397.
Rise Advisors first reported a position in Gyre Therapeutics in Q2 2025 and held it in 1 quarter.
Rise Advisors's Gyre Therapeutics position peaked at $397 in Q2 2025.
48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.

Based on Rise Advisors's 13F filing for Q3 2025, filed 8 Oct 2025.